PUBLIC SAFETY TOPICS
Anthrax
Symptoms of disease vary depending on how the disease was contracted, but usually occur within 7 days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax.
Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal.
The intestinal disease form of anthrax may follow the consumption of contaminated food and is characterized by an acute inflammation of the intestinal tract. Initial signs of nausea, loss of appetite, vomiting, and fever are followed by abdominal pain, vomiting of blood, and severe diarrhea.
Direct person-to-person spread of anthrax is extremely unlikely, if it occurs at all. Therefore, there is no need to immunize or treat contacts of persons ill with anthrax, such as household contacts, friends, or coworkers, unless they also were also exposed to the same source of infection.
In persons exposed to anthrax, infection can be prevented with antibiotic treatment. Early antibiotic treatment of anthrax is essential-delay lessens chances for survival. Anthrax usually is susceptible to penicillin, doxycycline, and fluoroquinolones.
An anthrax vaccine also can prevent infection. Vaccination against anthrax is not recommended for the general public to prevent disease and is not available.
Pneumonic Plaque
Pneumonic plague occurs when Y. pestis infects
the lungs. The first signs of illness in pneumonic plague are fever, headache,
weakness, and cough productive of bloody or watery sputum. The pneumonia
progresses over 2 to 4 days and may cause septic shock and, without early
treatment, death.
Person-to-person transmission of pneumonic plague
occurs through respiratory droplets, which can only infect those who have
face-to-face contact with the ill patient.
Early treatment of pneumonic plague is essential.
Several antibiotics are effective, including streptomycin, tetracycline,
and chloramphenicol.
There is no vaccine against plague.
Prophylactic antibiotic treatment for 7 days will
protect persons who have had face-to-face contact with infected patients.
This material has been developed by the Centers for Disease Control and
Prevention. Reuse or reproduction of this material is authorized. Information
updated, September, 2001.
Smallpox
Smallpox is caused by variola virus. The incubation
period is about 12 days (range: 7 to 17 days) following exposure. Initial
symptoms include high fever, fatigue, and head and back aches. A characteristic
rash, most prominent on the face, arms, and legs, follows in 2-3 days.
The rash starts with flat red lesions that evolve at the same rate. Lesions
become pus-filled and begin to crust early in the second week. Scabs develop
and then separate and fall off after about 3-4 weeks. The majority of
patients with smallpox recover, but death occurs in up to 30% of cases.
Smallpox is spread from one person to another by
infected saliva droplets that expose a susceptible person having face-to-face
contact with the ill person. Persons with smallpox are most infectious
during the first week of illness, because that is when the largest amount
of virus is present in saliva. However, some risk of transmission lasts
until all scabs have fallen off.
Routine vaccination against smallpox ended in 1972.
The level of immunity, if any, among persons who were vaccinated before
1972 is uncertain; therefore, these persons are assumed to be susceptible.
Vaccination against smallpox is not recommended
to prevent the disease in the general public and therefore is not available.
In people exposed to smallpox, the vaccine can
lessen the severity of or even prevent illness if given within 4 days
after exposure. Vaccine against smallpox contains another live virus called
vaccinia. The vaccine does not contain smallpox virus.
The United States currently has an emergency supply
of smallpox vaccine.
There is no proven treatment for smallpox but research
to evaluate new antiviral agents is ongoing. Patients with smallpox can
benefit from supportive therapy (intravenous fluids, medicine to control
fever or pain, etc.) and antibiotics for any secondary bacterial infections
that occur.
This material has been developed by the Centers for Disease Control and Prevention. Reuse or reproduction of this material is authorized. Information updated, September, 2001.
Home | Meet the Doctors | Online Forms | Newsletter | Contact Info